甲基1,2,3,4-四-O-异丁酰基-beta-D-葡萄糖醛酸酯 | 150607-94-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 甲基1,2,3,4-四-O-异丁酰基-beta-D-葡萄糖醛酸酯
• 中文别名: 甲基1,2,3,4-四-O-异丁酰-β-D-葡萄吡喃糖醛酸酯
• 英文名称: methyl 1,2,3,4-tetra-O-isobutyryl-β-D-glucopyranuronate
• 英文别名: Methyl 1,2,3,4-tetra-o-isobutyryl-beta-d-glucopyranuronate；methyl (2S,3S,4S,5R,6S)-3,4,5,6-tetrakis(2-methylpropanoyloxy)oxane-2-carboxylate
• CAS: 150607-94-6
• 化学式: C₂₃H₃₆O₁₁
• 分子量: 488.532
• InChiKey: RFMOIPHVGPMCMF-RLAOKGOQSA-N

物化性质

• 熔点：
  126-128°C
• 沸点：
  499.3±45.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、乙酸乙酯

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  34
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  141
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  甲基1,2,3,4-四-O-异丁酰基-beta-D-葡萄糖醛酸酯 在 sodium hydroxide 、 三氟化硼 、 氨 、 水 、 sodium carbonate 作用下， 以 二氯甲烷 为溶剂， 生成 N-(4-aminobutyl)normorphine-6-β-D-glucuronide
  参考文献：
  名称：

  Synthesis of a morphine-6-glucuronide hapten, N-(4-aminobutyl)normorphine-6-glucuronide, and related haptens

  摘要：

  For use as a hapten in the radioimmunoassay of morphine-6-glucuronide 2 (M6G), N-(4-aminobutyl)normorphine-6-glucuronide 12 has been prepared, together with related haptens, using the imidate coupling method developed for synthesis of M6G; a rebuttal of recent critical comments on our synthesis of M6G is included.

  DOI：

  10.1016/0040-4039(95)01786-h
• 作为产物：
  描述：

  D-glucurono-6,3-lactone 在 吡啶 作用下， 生成 甲基1,2,3,4-四-O-异丁酰基-beta-D-葡萄糖醛酸酯
  参考文献：
  名称：

  Synthesis of a morphine-6-glucuronide hapten, N-(4-aminobutyl)normorphine-6-glucuronide, and related haptens

  摘要：

  For use as a hapten in the radioimmunoassay of morphine-6-glucuronide 2 (M6G), N-(4-aminobutyl)normorphine-6-glucuronide 12 has been prepared, together with related haptens, using the imidate coupling method developed for synthesis of M6G; a rebuttal of recent critical comments on our synthesis of M6G is included.

  DOI：

  10.1016/0040-4039(95)01786-h

文献信息

• 6-O-Glycosylation of Morphine Derivatives Using Thioglycosides as Glycosyl Donors
  作者：Igor Rukhman、Lev Yudovich、Gennadiy Nisnevich、Arie L. Gutman

  DOI：10.1055/s-2000-6413

  日期：——

  A novel approach was developed for the synthesis of the pharmaceutically important morphine and dihydromorphine 6-β-d-glucuronides. The key step involves a selective 6-O-glycosylation of 3-O-protected morphines and dihydromorphines with thioglycosides that serve as glycosyl donors in the presence of thiophilic promoters. This novel approach may be useful for the O-glycosylation of other alkaloid derivatives.

  针对合成在医药领域重要的吗啡和二氢吗啡-6-β-d-葡萄糖醛酸苷，开发了一种新颖的方法。关键步骤包括在硫亲和助推剂存在下，利用硫代糖苷作为糖基供体，对3-O-保护的吗啡和二氢吗啡进行选择性的6-O-糖基化反应。这一新颖方法可能对其他生物碱衍生物的O-糖基化具有应用价值。
• Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
  申请人：Galantos Pharma GmbH

  公开号：EP1777222A1

  公开（公告）日：2007-04-25

  The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline of neuronal cholinergic receptors and/or acting as chvlinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g. galanthamine, narwedine and lyeoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as "prodrugs", in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments for the treatment of human brain diseases associated with a cholinergic deficit, including the neurodegenerative diseases Alzheimer's and Parkinson's disease and the psychiatric diseases vascular dementia, schizophrenia and epilepsy.

  本发明涉及化合物，除了增强神经胆碱能受体对乙酰胆碱和胆碱的敏感性，或者作为胆碱酯酶抑制剂和/或神经保护剂之外，与其原始化合物相比具有增强的血脑屏障渗透性。这些化合物来源于属于石蒜科生物碱类的天然化合物，例如迎春碱、纳尔韦丁和莱奥拉明，或者来源于这些化合物的代谢物（无论是从化学结构上还是直接通过化学合成）。本发明的化合物可以直接与其靶分子相互作用，或者它们可以作为“前药”，意味着在到达体内的靶区域后，它们通过水解或酶攻击转化为原始的母体化合物，并且与其靶分子相互作用，或者两者兼而有之。本发明的化合物可用作治疗与胆碱缺乏相关的人类脑疾病的药物，包括神经退行性疾病阿尔茨海默病和帕金森病，以及精神疾病血管性痴呆、精神分裂症和癫痫。
• CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT
  申请人：Maelicke Alfred

  公开号：US20070213318A1

  公开（公告）日：2007-09-13

  The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g. galanthamine, narwedine and lycoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as “pro-drugs”, in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments for the treatment of human brain diseases associated with a cholinergic deficit, including the neurodegenerative diseases Alzheimer's and Parkinson's disease and the psychiatric diseases vascular dementia, schizophrenia and epilepsy.

  本发明涉及化合物，除了增强神经元胆碱能受体对乙酰胆碱和胆碱的敏感性，或者作为胆碱酯酶抑制剂和/或神经保护剂外，与其母化合物相比，具有增强的血脑屏障渗透性。这些化合物是从天仙子科生物碱类天仙子碱，如无心菜碱、纳尔韦丁和百合碱，或其代谢物中派生的（通过其化学结构或直接通过化学合成）。本发明的化合物可以直接与其目标分子相互作用，也可以作为“前药”，在到达体内目标区域后，通过水解或酶攻击转化为原始母化合物，并像母化合物一样与其目标分子反应，或两者兼而有之。本发明的化合物可用作治疗与胆碱能缺陷相关的人类脑疾病的药物，包括神经退行性疾病阿尔茨海默病和帕金森病以及精神疾病血管性痴呆、精神分裂症和癫痫。
• Cholinergic Enhancers with Improved Blood-Brain Barrier permeability for the Treatment of Diseases Accompanied by Cognitive Impairment
  申请人：Maelicke Alfred

  公开号：US20080261954A1

  公开（公告）日：2008-10-23

  The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g. Galanthamine, narwedine and lycoramine, or from metabolites of said compounds.

  本发明涉及一种化合物，除了增强神经元胆碱能受体及外源性激动剂对乙酰胆碱和胆碱的敏感性，以及作为胆碱酯酶抑制剂和/或神经保护剂外，还具有比其母体化合物更强的血脑屏障通透性。这些化合物是从天仙子科生物碱（例如迎春花碱，纳威丁和莲花碱）或其代谢物中衍生出来的（可以通过其化学结构或直接通过化学合成来实现）。
• Convenient syntheses of deoxypyranose sugars from glucuronolactone
  作者：Deborah Stanford (nee Sinnott)、Andrew V. Stachulski

  DOI：10.1016/j.tetlet.2007.01.127

  日期：2007.3

  acid derivatives is the base-catalysed elimination of a 4-(substituted) hydroxy group to generate a Δ4,5 pyranose. Following hydrogenation, proceeding mainly from the α-face provided the anomeric configuration is β, the initial C(5)-configuration is restored. This sequence affords access to a number of 4-deoxypyranoses: thus 4-deoxyglucoses are readily available by reduction at C(6). Conversion to a

  一个葡糖醛酸衍生物的特征的反应是4-（取代的）羟基的碱催化的消除，以生成Δ 4,5吡喃糖。氢化后，主要从α面开始，只要端基异构体构型为β，即可恢复初始C（5）构型。该序列提供了进入多个4-脱氧吡喃糖的途径：因此，通过在C（6）还原可容易地获得4-脱氧葡萄糖。转换为糖基，然后在C（2）/ C（3）处进行顺二羟基化反应，形成d- lyxo构型（在新霉素中发现）。最后，再次通过二羟基化显示出与KDO系列的不太明显的关系。